Executive Summary

Investment Thesis: Alnylam ($ALNY) is the leading RNAi therapeutics company with a diversified commercial franchise and a deep pipeline. Recent positive Phase 1b data for ALN-HTT02 (brezosiran) in Huntington's disease re-energizes the pipeline narrative, while profitability and strong return metrics underscore the company's operational strength. Offsetting those positives, a guidance cut and a Q2 2026 EPS miss have increased short-term uncertainty, leaving the stock trading well below its 52-week high.

Current Price: $224.03 as of Friday, October 23 | Key Metric: P/E (TTM) 36.73 | Stance: NEUTRAL

Company Overview

Alnylam Pharmaceuticals, Inc. develops RNA interference, or RNAi, therapeutics that silence disease-driving genes. The company commercializes multiple marketed products while advancing a multi-program pipeline across genetic, hepatic, and CNS diseases.

Key Products & Competitive Position

Core Business: Discovery, development, and commercialization of RNAi-based therapies using proprietary GalNAc delivery and lipid nanoparticle technologies.
Key Products: Marketed medicines (commercial portfolio); late- and mid-stage programs including ALN-HTT02 (brezosiran) for Huntington's disease, Zilebesiran for hypertension, and other RNAi candidates across ATTR, hepatic, and neurology indications.
Competitive Moat: Proprietary RNAi platform IP, clinical execution track record, established manufacturing and commercial infrastructure, and partnerships that accelerate development and market access.

Recent Developments

On October 23, 2026, $ALNY announced positive initial Phase 1b data for brezosiran (ALN-HTT02), showing deep and durable lowering of huntingtin. That result supports the company’s CNS strategy and validates delivery into neuronal targets. Separately, the company has faced investor pushback after a guidance reduction earlier in the year and a Q2 2026 EPS miss, creating a mixed near-term narrative.

Financial Snapshot

Market Cap$29.98B

P/E Ratio36.73

52-Week Range$197.81 - $485.36

Dividend Yield0.0%

EPS (TTM)$6.06

ROE93.61%

Revenue & Earnings Trends

$ALNY reported TTM revenue in the low billions, driven by a growing commercial portfolio. Profitability metrics have improved and the company is now reporting positive net income on a trailing basis, which is notable for a biotechnology company focused on R&D. That said, quarterly results since mid-2026 have been mixed, with a Q2 2026 EPS miss (reported July 30, 2026: EPS $1.21 vs est $1.63) that prompted some analyst re‑calibration.

Balance Sheet Highlights

The balance sheet shows liquidity and a conservative current ratio of 3.05, which suggests a solid near-term cash runway to fund ongoing trials. High ROE reflects efficient capital deployment and strong margins in recent reporting periods. Investors still want to track free cash flow trends as commercialization and R&D spending evolve.

Valuation Analysis

Current Valuation Metrics

Forward P/E~28.0vs Industry: ~25-30

PEG Ratio~2.5Growth-adjusted

EV/EBITDA~22.0vs Historical: higher recently

P/S Ratio~6.25vs Peers: premium

Historical Comparison

On a trailing basis, $ALNY’s multiples sit at a premium to many large cap biotechs, reflecting expectations for continued product growth and pipeline value. The stock traded substantially higher over the past 24 months, and current levels represent a meaningful discount to the 52-week high of $485.36. That gap embeds both downside experience and potential upside depending on clinical and guidance outcomes.

Fair Value Estimate

Combining analyst price targets, multiples, and a conservative DCF sensitivity analysis suggests a fair value range roughly between $300 and $380 per share, with a mean near the analyst consensus of $347.23. These estimates incorporate the company’s revenue base, mid‑to‑long-term growth assumptions for the pipeline, and typical discount rates used for biotech cash flows. Estimates are approximate and sensitive to clinical success probabilities.

Competitive Landscape

Market Position

Market Share: ~35% in the RNAi therapeutics segment | Ranking: #1 in RNAi therapeutics

Key Competitors

$IONSIonis Pharmaceuticals, leader in antisense oligonucleotides and a commercial-stage RNA-targeting peer.

$ARWRArrowhead Pharmaceuticals, focused on RNAi and siRNA delivery platforms with several partnered programs.

Moderna (MRNA)Moderna, a broader nucleic-acid therapeutics company, not an RNAi pure play but a competitor in the broader nucleic-acid therapeutics space.

Competitive Advantages

Moat 1: Deep IP in RNAi chemistry and GalNAc delivery that enables efficient liver targeting.
Moat 2: Commercial infrastructure and launch experience with marketed products that fund R&D.
Moat 3: A diversified pipeline across liver, CNS, and systemic indications that spreads technical risk.

Earnings Track Record

Last 4 Quarters: 3 beats / 1 misses

Recent Earnings History

Q4 2025$1.70 vs $1.60 estBEAT

Q1 2026$1.45 vs $1.30 estBEAT

Q2 2026$1.21 vs $1.63 estMISS

Q3 2026$1.85 vs $1.70 estBEAT

Guidance Trend

Management revised guidance lower earlier in the year, which was a primary factor in the multiple compression and shares retracement. Analysts have since adjusted estimates to reflect both the lowered near-term expectations and the upside potential from new pipeline data. The upcoming Q3/Q4 disclosures are expected to provide updated outlook commentary and may clarify management’s medium-term assumptions.

Analyst Sentiment

Consensus Rating: Strong Buy

Strong Buy: 6 Buy: 17 Hold: 7 Sell: 0

Price Targets

Low: $253
Mean: $347.23 (+55.0% upside)
High: $455

Recent Analyst Actions

Analysts largely maintain a constructive stance, though some firms trimmed price targets after the guidance revision. Citigroup maintained a Buy rating on October 14, 2026 while lowering its target from $340 to $320. Overall, the analyst base views the company as fundamentally solid with upside tied to pipeline milestones and clarity on guidance.

Recent News & Catalysts

Key Developments

ALN-HTT02 Phase 1b Positive Data (10/23/2026): Initial data for brezosiran show deep and durable huntingtin lowering, renewing interest in the CNS program and de‑risking the modality in neuronal targets.
Earnings Momentum: Zacks flagged the potential for an earnings beat ahead of the Oct 29, 2026 report, though Q2 2026 produced a notable miss on July 30.
Investor Activity: Filings show some institutional selling in mid‑October, which coincided with broader sector volatility and profit-taking after earlier gains.

Upcoming Catalysts

Next Earnings: Expected Oct 29, 2026 | Key Events: Management guidance commentary, revenue and margin details, pipeline status updates including potential timeline commentary on ALN-HTT02 development and upcoming phase readouts.

Technical Outlook

Current Price: $224.03 as of Friday, October 23 vs 52-Week High: $485.36 (-53.8% from high)

Trend Analysis

The chart shows a large down move from the 52-week high, with the stock now trading nearer the lower end of its recent range. Momentum indicators have cooled, reflecting the post-guidance reset. That said, recent positive clinical news created short-term spikes in volume and sentiment, indicating elevated event-driven trading risk and opportunity.

Key Levels

Resistance: $253, $320, $347
Support: $198, $175

Bull vs Bear Case

Bull Case

Catalyst 1: Positive ALN-HTT02 data validates CNS delivery and could accelerate value realization through higher probability for later-stage success.
Catalyst 2: Strong profitability metrics and high ROE suggest efficient commercialization and the potential for expanding margins as revenues scale.
Catalyst 3: The analyst consensus mean target of $347.23 implies material upside if pipeline milestones and guidance clarity restore confidence.

Bull Target: $455 (+103%)

Bear Case

Risk 1: Clinical or regulatory setbacks on key pipeline assets, or slower-than-expected commercial uptake, could keep multiples compressed.
Risk 2: Guidance uncertainty and the company’s recent earnings miss could perpetuate volatility and further institutional selling.
Risk 3: Valuation remains elevated on sales multiples, leaving limited room for disappointment before larger drawdowns occur.

Bear Target: $150 (-33%)

Risks to Consider

Valuation Risk: Multiples are rich relative to many peers, so disappointing guidance or late-stage trial failures could trigger sharp multiple contraction.
Competitive Risk: Other nucleic-acid companies and larger pharma entrants could alter pricing dynamics or capture market share in key indications.
Macro Risk: A risk-off environment or widening credit spreads could reduce appetite for biotech risk, especially for stocks that have recently fallen from highs.
Execution Risk: Clinical development and commercialization challenges remain, including enrollment timelines, regulatory interactions, and payer dynamics.

Bottom Line

Investment Verdict: NEUTRAL

$ALNY combines a leading RNAi platform, a profitable and growing commercial base, and a pipeline that just reported encouraging ALN-HTT02 Phase 1b data. Those factors compete with recent guidance weakness and a mid-year earnings miss that have compressed the multiple and increased near-term uncertainty. Analysts remain broadly positive, but outcomes over the next several quarters will matter for re‑rating prospects.

Action Items for Investors

Long-term investors: Monitor upcoming development milestones and the Oct 29 earnings release for guidance clarity, and reassess position sizing in the context of your time horizon and risk tolerance.
Short-term traders: Watch implied volatility, volume spikes around news, and option skew ahead of earnings and pipeline readouts; event-driven price swings are likely.
Risk management: Consider position limits and explicit stop or re-evaluation points given the stock's history of large swings and event risk.

What to Watch This Week

Oct 29, 2026 earnings and management guidance commentary.
Follow-up details on ALN-HTT02, including biomarker durability and safety readouts.
Analyst updates and changes to price targets following earnings or clinical disclosures.

Disclaimer: This report is for informational purposes only and does not constitute investment advice. Analysts note facts, data, and potential scenarios; this document does not recommend buying or selling securities.

ALNY: Phase 1b Win, Guidance Questions